• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Virta Health Helps AutoZone Employees Reverse Type 2 Diabetes

by Jasmine Pennic 12/01/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Type 2 diabetes reversal leader Virta Health revealed promising one-year outcomes from its partnership with AutoZone, Inc., a retailer and distributor of automotive replacement parts and accessories in the Americas.

– Virta provides virtual, continuous health coaching, medical supervision and personalized nutrition to help patients reverse their metabolic disease, lose weight, + get off medications. At one year, AutoZoners experience long-term blood sugar control and clinically-significant weight loss while eliminating over half of diabetes medications.

AutoZone’s Health Outcomes for Employees

AutoZone currently offers Virta’s type 2 diabetes reversal, prediabetes reversal, type 2 diabetes management, and obesity and weight loss solutions to eligible AutoZoners at no-cost. Over the past twelve months, AutoZoners living with type 2 diabetes, prediabetes, and obesity have achieved transformative results with Virta, including:

– Medication Deprescription: Type 2 diabetes patients eliminated over half of diabetes medications (excluding metformin), including a 73% reduction in insulin prescribed after 12 months.

– Blood Sugar Reduction: Estimated HbA1c (a measure of average blood sugar) improved by 1% on average for diabetes patients. Every one-point decrease in HbA1c reduces the risk of long-term diabetes complications—such as eye, kidney, and nerve disease—by up to 40%.

– Clinically Significant Weight Loss: Across all groups, patients saw at least 8% weight loss on average (5% is the benchmark for FDA-approved weight-loss drugs and what is considered clinically significant). AutoZoners enrolled in Virta’s obesity program experienced 9% weight loss.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: diabetes, Diabetes Management, Diabetes Reversal, FDA, insulin, medication, Obesity, risk, Type 2 Diabetes, Virta Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |